Suppr超能文献

BCLAF1 对 HDAC 抑制剂 LMK-235 介导的弥漫性大 B 细胞淋巴瘤细胞凋亡的影响及其机制。

Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.

机构信息

a Guizhou Medical University , Guiyang , Guizhou , China.

d Guizhou Province Laboratory of Haematopoietic Stem Cell Transplantation Center , Guiyang , Guizhou , China.

出版信息

Cancer Biol Ther. 2018;19(9):825-834. doi: 10.1080/15384047.2018.1472188. Epub 2018 Jul 3.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult lymphoma. It is a group of malignant tumors with a large number of clinical manifestations and prognoses. Therefore, it is necessary to explore its unknown potential therapeutic targets. Histone deacetylase inhibitor (HDACi) is a novel drug for the treatment of DLBCL, however pan-HDACis cannot be ignored because of their clinical efficacy. By contrast, specific HDACi is well-tolerated, and LMK-235 is a novel HDACi that is a specific inhibitor of HDAC4 and HDAC5. In this study, we investigated the up-regulation of BCLAF1 through NF-κB signaling pathways in LMK-235, mediating the apoptosis of two diffuse large B-cell lymphoma cell lines, OCI-LY10 and OCI-LY3. Further studies showed that BCLAF1 expression was increased in DLBCL cells after treatment with the NF-κB inhibitor Bay11-7082. The combination of Bay11-7082 and siRNA si-HDAC4 significantly increased BCLAF1 expression and further increased apoptosis. These results indicate that BCLAF1 plays an important role in LMK-235-mediated apoptosis and may be a potential target for the treatment of diffuse large B-cell lymphoma.

摘要

弥漫性大 B 细胞淋巴瘤(DLBCL)是成人淋巴瘤中最常见的类型。它是一组临床表现和预后差异较大的恶性肿瘤。因此,有必要探索其未知的潜在治疗靶点。组蛋白去乙酰化酶抑制剂(HDACi)是治疗 DLBCL 的新型药物,但 pan-HDACi 因其临床疗效而不容忽视。相比之下,特异性 HDACi 具有良好的耐受性,而 LMK-235 是一种新型的 HDACi,它是 HDAC4 和 HDAC5 的特异性抑制剂。在这项研究中,我们通过 NF-κB 信号通路研究了 LMK-235 上调 BCLAF1 在两种弥漫性大 B 细胞淋巴瘤细胞系 OCI-LY10 和 OCI-LY3 中的作用,介导其凋亡。进一步的研究表明,NF-κB 抑制剂 Bay11-7082 处理后,DLBCL 细胞中 BCLAF1 的表达增加。Bay11-7082 和 siRNA si-HDAC4 的联合使用显著增加了 BCLAF1 的表达,并进一步增加了细胞凋亡。这些结果表明,BCLAF1 在 LMK-235 介导的凋亡中起重要作用,可能是治疗弥漫性大 B 细胞淋巴瘤的潜在靶点。

相似文献

1
Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.
Cancer Biol Ther. 2018;19(9):825-834. doi: 10.1080/15384047.2018.1472188. Epub 2018 Jul 3.
7
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Int J Mol Sci. 2018 Oct 12;19(10):3128. doi: 10.3390/ijms19103128.

引用本文的文献

2
LMK-235 suppresses osteoclastogenesis and promotes osteoblastogenesis by inhibiting HDAC4.
Sci Rep. 2024 Aug 28;14(1):19973. doi: 10.1038/s41598-024-70814-8.
4
Pan-Cancer Analysis Identifies BCLAF1 as a Potential Biomarker for Renal Cell Carcinoma.
Biochem Genet. 2025 Apr;63(2):1479-1508. doi: 10.1007/s10528-024-10773-x. Epub 2024 Apr 4.
7
Function of BCLAF1 in human disease.
Oncol Lett. 2022 Feb;23(2):58. doi: 10.3892/ol.2021.13176. Epub 2021 Dec 22.
9
BCLAF1 induces cisplatin resistance in lung cancer cells.
Oncol Lett. 2020 Nov;20(5):227. doi: 10.3892/ol.2020.12090. Epub 2020 Sep 11.

本文引用的文献

2
Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):85-96. doi: 10.1016/j.bbcan.2018.01.001. Epub 2018 Jan 11.
3
miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
Leukemia. 2018 Feb;32(2):573. doi: 10.1038/leu.2017.310. Epub 2017 Dec 22.
5
Diffuse large B-cell lymphoma.
Pathology. 2018 Jan;50(1):74-87. doi: 10.1016/j.pathol.2017.09.006. Epub 2017 Nov 20.
6
Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor and .
Oncotarget. 2017 Jul 28;8(45):78480-78495. doi: 10.18632/oncotarget.19652. eCollection 2017 Oct 3.
7
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.
9
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
J Natl Cancer Inst. 2016 Dec 16;108(12). doi: 10.1093/jnci/djw257. Print 2016 Dec.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验